TCBP

TC BioPharm (Holdings) plc [TCBP] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TCBP Stock Summary

In the News

TCBP Financial details

Company Rating
-
Market Cap
1.66M
Income
0
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
41
Optionable
No
Shortable
Yes
Earnings
28 Aug 2024
P/E
-0.87
Forward P/E
-
PEG
-
P/S
0.31
P/B
-47.09
P/C
-
P/FCF
-0.08
Quick Ratio
0.72
Current Ratio
0.81
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0
EPS next Y
-
EPS next Q
-
EPS this Y
-52.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-38.38%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-77.78%
SMA50
-94.36%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-13%
ROE
17%
ROC
-6.75%
Gross Margin
100%
Oper. Margin
-314%
Profit Margin
-36%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.85-440.0
52W High
-
52W Low
-
RSI
39.39
Rel Volume
-
Avg Volume
4.8M
Volume
1.63K
Perf Week
81.41%
Perf Month
-74.88%
Perf Quarter
-
Perf Half Y
-94.77%
-
-
-
-
Beta
0.328
-
-
Volatility
0.1%, 0.65%
Prev Close
81.41%
Price
0.4898
Change
22.45%

Something similar

Top by Market Cap
AVGO
NVDA
GOOG
BRYN.DE
FXAIX
Same Sector
MDVL
MJNE
FMS
0J1R.L
CRNX
Check Those
AEE
SAV.L
0577.HK
002473.SZ
002539.SZ
Similar Market Cap
HMJI.TO
ALTX
MLJSA.PA
KMED
EMRJ.L

Company Profile

Healthcare Biotechnology
  • Volume Average 4.8M
  • Market Capitalization 1.66M
  • Employee 41
  • CEO Mr. Bryan L. Kobel
  • Headquarters Motherwell,GB
  • IPO Date 2022-02-11
  • Website https://www.tcbiopharm.com

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.